- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC
June 5th 2022, 9:38pm
The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.
Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma
June 5th 2022, 9:05pm
Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.
177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel
June 5th 2022, 8:31pm
177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities
Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma
June 5th 2022, 7:50pm
Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.
Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer
June 5th 2022, 7:40pm
Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.
Selpercatinib Demonstrates Promising Activity in RET Fusion-Positive Solid Tumors
June 5th 2022, 7:25pm
Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.
Zenocutuzumab Showcases Robust, Durable Efficacy in Advanced NRG1+ Cancer, Irrespective of Tumor Histology
June 5th 2022, 7:15pm
Zenocutuzumab was found to produce durable responses in patients with previously treated advanced NRG1-positive cancers, with antitumor activity observed across several tumor types, and to have an extremely well tolerated toxicity profile, according to data from a phase 1/2 trial (NCT02912949).
Daratumumab and Carfilzomib Quadruplet Elicits Efficacy and Safety Benefits in High-Risk Multiple Myeloma
June 5th 2022, 6:50pm
Induction therapy with the quadruplet regimen of daratumumab, carfilzomib, lenalidomide, and dexamethasone appears to be feasible in patients with high-risk, newly diagnosed multiple myeloma who are eligible for transplant, displaying safety benefits and responses.
Liso-cel Elicits Significant Second-line Activity in Frail Patients with Relapsed/Refractory LBCL
June 5th 2022, 6:25pm
Treatment with lisocabtagene maraleucel resulted in a high rate of durable overall and complete responses as second-line therapy in frail patients with relapsed/refractory large B-cell lymphoma for whom hematopoietic stem cell transplantation was not intended, according to preliminary findings from the phase 2 PILOT study.
Ixazomib/Daratumumab Elicits Encouraging Response in Elderly Frail Patients With R/R Multiple Myeloma
June 5th 2022, 6:05pm
Ixazomib plus daratumumab without dexamethasone showed a positive efficacy profile for elderly frail patients with relapsed/refractory multiple myeloma, according to results of the phase 2 IFM 2018-02 study.
Panitumumab/mFOLFOX Establishes Prominent Role in RAS Wild-Type Metastatic CRC
June 5th 2022, 5:40pm
The addition of panitumumab to mFOLFOX6 improved outcomes for patients with left-sided RAS wild-type metastatic colorectal cancer compared with bevacizumab and chemotherapy in the front-line setting, according to results from the phase 3 PARADIGM trial.
Lenvatinib Plus Pembrolizumab Improves PFS2 Outcomes in Advanced RCC
June 5th 2022, 5:15pm
Patients with advanced renal cell carcinoma who received lenvatinib plus pembrolizumab experienced a longer time to progression on next line of therapy compared with those who received sunitinib.
Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC
June 5th 2022, 4:45pm
Treatment with fam-trastuzumab deruxtecan-nxki doubled progression-free survival and reduced the risk of death by 36% compared with physician's choice of chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer.
Daratumumab Plus RVd Demonstrates Durable MRD Negativity in Multiple Myeloma
June 5th 2022, 3:45pm
Daratumumab plus induction/consolidation lenalidomide, bortezomib, and dexamethasone elicited higher minimal residual disease-negativity rates vs the RVd combination alone in patients with transplant-eligible newly diagnosed multiple myeloma, including those in high-risk subgroups.
RVd Plus Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma
June 5th 2022, 3:44pm
The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
Biomarker Analysis Confirms Benefit of Alpelisib Plus Fulvestrant Regardless of Mutation Status in HR+/HER- Breast Cancer
June 5th 2022, 3:23pm
Alpelisib plus fulvestrant demonstrated a clinical benefit regardless of gene mutation status in patients with hormone receptor–positive, HER2-negative advanced breast cancer, including those with FGFR1 or FGFR2 alterations.
CT041 CAR T-cell Therapy Elicits Manageable Toxicity and Durable Response in Gastric/GEJ Cancer
June 5th 2022, 3:00pm
CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.
Lenvatinib Plus Pembrolizumab Bolsters PFS2 Outcomes in Advanced Endometrial Cancer
June 5th 2022, 11:45am
The combination of lenvatinib and pembrolizumab demonstrated clinically meaningful improvements in progression-free survival on next line of therapy among all-comer patients with advanced endometrial cancer and those with DNA mismatch repair proficient disease, according to an exploratory analysis of the phase 3 KEYNOTE-775 trial.
Ribociclib Plus Switch Endocrine Therapy Elicits Benefit After CDK4/6 Progression in HR+/HER2– Metastatic Breast Cancer
June 5th 2022, 11:35am
Ribociclib plus endorcrine therapy led to a statistically significant improvement in progression-free survival in patients with hormone receptor–positive, HER2-negative unresectable or metastatic breast cancer with tumor progression following treatment with a CDK4/6 inhibitor, according to findings from the randomized phase 2 MAINTAIN trial.
Preview of ASCO 2022: Dr Everett Vokes
June 5th 2022, 1:05am
OncLive News Network: On Location at ASCO 2022
OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.